The Alexander project 1998-2000: Susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 2, 2003, Pages 229-246

  Jacobs, Michael R ^a   Felmingham, David ^c   Appelbaum, Peter C ^b   Grüneberg, Reuben N ^c   Kariuki, S ^c   Klugman, K ^c   Urbaskova P ^c   Hryniewicz, W ^c   Sidorenko, S V ^c   Upkova H ^c   Theuretzbacher, U ^c   Verhaegen, J ^c   Lemozy, J ^c   Dabernat, H ^c   Goldstein, F ^c   Weber, M ^c   Roussel Delvallez, M ^c   Jehl, F ^c   Grimm, H ^c   Seewald, M ^c   Mauch, H ^c   Giamarellou, H ^c   Schito, G C ^c   Stobberingh, E E ^c   Cristino, J M ^c   Smyth, E ^c   Gilleece, A ^c   Fenelon, L ^c   Linares J ^c   Bille, J ^c   Felmingham, D ^c   Wing Hong, S ^c   Yamaguchi, K ^c   Kono, S ^c   Inoue, M ^c   Kaku, M ^c   Yeo, M ^c   Lin, R ^c   Keller, N ^c   Shibl, A M ^c   Mendes, C ^c   Sifuentes Osornio, J ^c   Quinones F ^c   Espinosa, L E ^c   Alvarez, G ^c   Ma Hinojosa, R ^c   Tinoco, J C ^c   Ojeda, F ^c   Grover, B ^c   Gamble, S ^c   Bay, M ^c   Lamb, D ^c   Munroe, S ^c   Teskie, G ^c   Wong, P ^c   Cyprian, S ^c   Cleary, T ^c   Rivera, M ^c   Watkins, C ^c   Phillips, H ^c   Prince, D ^c   Walker, S ^c   Beard, M ^c   Carey, R ^c   Droege, B ^c   Tjhio, J ^c   Denys, G ^c   Cheek, R ^c   Munier, G ^c   Cato, B ^c   Eppling, W ^c   Cosmidis, D ^c   DeMarco, D ^c   McDermott, L ^c   Schwartz, D ^c   Welty, M ^c   VanEnk, R ^c   Loomis, J ^c   McClure, L ^c   Temme, L ^c   Matthey, S ^c   Hostetter, M ^c   Buck, L ^c   Overturf, G ^c   Cammarata, R ^c   Jenkins, S ^c   Rosenstein, L ^c   DiPersio, J R ^c   Jacobs, M ^c   Hogan, C ^c   Rourke, B ^c   Kaufmann, L ^c   Griffin, J ^c   Smith, B ^c   Brown, L ^c   Cavagnolo, B ^c   Lee, N ^c   Mann, L ^c   Korgenski, K ^c   more..

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c NONE

Author keywords

Antimicrobial resistance; Community acquired respiratory tract infection; Haemophilus influenzae; Moraxella catarrhalis; Streptococcus pneumoniae; Surveillance

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFACLOR; CEFDINIR; CEFIXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME AXETIL; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; COMMUNICABLE DISEASE; CONTROLLED STUDY; DILUTION; DRUG POTENCY; EVOLUTION; GEOGRAPHICAL VARIATION (SPECIES); HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PENICILLIN RESISTANCE; PRESCRIPTION; PREVALENCE; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HAEMOPHILUS INFLUENZAE; HUMANS; INTERNATIONALITY; MORAXELLA (BRANHAMELLA) CATARRHALIS; POPULATION SURVEILLANCE; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0043156138     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg321     Document Type: Article

References (44)

1. Mandell, L. A. (1995). Community-acquired pneumonia: etiology, epidemiology and treatment. Chest 108, 35-42S.
2. Ball, P. (1995). Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 108, 43-52S.
3. Goldstein, F., Bryskier, A., Appelbaum, P. C. et al. (1998). The etiology of respiratory tract infections and the antibacterial activity of fluoroquinolones and other oral bacterial agents against respiratory pathogens. Clinical Microbiology and Infection 4, Suppl. 2, 2S8-18.
4. Felmingham, D. (1995). Antibiotic resistance: do we need new therapeutic approaches? Chest 108, 70-8S.
5. Felmingham, D., Grüneberg, R. N. & the Alexander Project Group. (1996). A multicenter collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: The Alexander Project. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 1-57.
6. Felmingham, D., Grüneberg, R. N. & the Alexander Project Group. (2000). The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 45, 191-203.
7. Grüneberg, R. N., Felmingham, D. & the Alexander Project Group. (1996). Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired, lower respiratory tract bacterial pathogens. Diagnostic Microbiology and Infectious Disease 25, 169-81.
8. National Committee for Clinical Laboratory Standards. (2002). Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement: Approved Standard M100-S12. NCCLS, Wayne, PA, USA.
9. Sinus and Health Allergy Partnership. (2000). Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngology-Head and Neck Surgery 123, Suppl., S1-32.
10. Christianson, J., Andes, D. & Craig, W. (2001). Characterization of the pharmacodynamics of doxycycline against Streptococcus pneumoniae in a murine thigh-infection model. In Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract A1103, p. 27. American Society for Microbiology, Washington, DC, USA.
11. Jacobs, M. R., Bajaksouzian, S., Zilles, A. et al. (1999). Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US Surveillance study. Antimicrobial Agents and Chemotherapy 43, 1901-8.
12. Preston, D. A., Turnak, M. R., Jacobs, M. R. et al. (2000). Assumed versus approved breakpoints. Antimicrobial Agents and Chemotherapy 44, 3243-5.
13. Jacobs, M. R. (2001). Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clinical Microbiology and Infection 11, 589-96.
14. Petitpretz, P., Chidiac, C., Soriano, F. et al. (2002). The efficacy and safety of pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxicillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. International Journal of Antimicrobial Agents 20, 119-29.
15. Mason, E. O., Jr, Lamberth, L. B., Kershaw, N. L. et al. (2000). Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis. Journal of Antimicrobial Chemotherapy 45, 623-31.
16. Jacobs, M. R., Bajaksouzian, S., Windau, A. et al. (2002). Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae. Journal of Clinical Microbiology 40, 3269-76.
17. Sutcliffe, J., Tait-Kamradt, A. & Wondrack, L. (1996). Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrobial Agents and Chemotherapy 40, 1817-24.
18. Gay, K., Baughman, W., Miller, Y. et al. (2000). The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. Journal of Infectious Diseases 182, 1417-24.
19. Marchandin, H., Jean-Pierre, H., Jumas-Bilak, E. et al. (2001). Distribution of macrolide resistance genes erm(B) and mef(A) among 160 penicillin-intermediate clinical isolates of Streptococcus pneumoniae isolated in southern France. Pathologie-biologie (Paris) 49, 522-7.
20. Grüneberg, R. N. (1996). The Alexander Project: using in vitro susceptibility data for choosing empirical therapy in LRTI. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 155-70.
21. Felmingham, D. & Washington, J. (1999). Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens-findings of the Alexander Project 1992-1996. Journal of Chemotherapy 11, Suppl. 1, 5-21.
22. Huebner, R. E., Wasas, A. D. & Klugman, K. P. (2000). Trends in antimicrobial resistance and serotype distribution of blood and cerebrospinal fluid isolates of Streptococcus pneumoniae in South Africa. International Journal of Infectious Diseases 4, 214-8.
23. Jones, R. N. & Pfaller, M. A. (2000). Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America 1997-1999). Journal of Clinical Microbiology 38, 4298-9.
24. Lonks, J. R., Garau, J., Gomez, L. et al. (2002). Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clinical Infectious Diseases 35, 556-64.
25. Hoban, D. J., Doern, G. V., Fluit, A. C. et al. (2001). Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clinical Infectious Diseases 32, Suppl. 2, S81-93.
26. Baquero, F. (1995). Pneumococcal resistance to β-lactam antibiotics: a global geographic overview. Microbial Drug Resistance 1, 115-20.
27. Pérez-Trallero, E., Fernández-Mazarrasa, C., García-Rey, C. et al. (2001). Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrobial Agents and Chemotherapy 45, 3334-40.
28. Chen, D. K., McGeer, A., De Azavedo, J. C. et al. (1999). Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. New England Journal of Medicine 341, 233-9.
29. Ho, P. L., Yam, W. C., Cheung, T. K. et al. (2001). Fluoroquinolone resistance among Streptococcus pneumoniae in Hong Kong linked to the Spanish 23F clone. Emerging Infectious Diseases 7, 906-8.
30. Clairoux, N., Picard, M., Brochu, A. et al. (1992). Molecular basis of the non-β-lactamase-mediated resistance to β-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada. Antimicrobial Agents and Chemotherapy 36, 1504-13.
31. Doern, G. V., Brueggemann, A. B., Pierce, G. et al. (1997). Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase positive strains resistant to amoxycillin-clavulanate: results of a national multicenter surveillance study. Antimicrobial Agents and Chemotherapy 41, 292-7.
32. Cars, O. (2001). Steering an appropriate course: principles to guide antibiotic choice. Respiratory Medicine 95, Suppl. A, S20-25.
33. Cars, O., Mölstad, S. & Melander, A. (2001). Variation in antibiotic use in the European Union. Lancet 357, 1851-3.
34. Baquero, F. & Negri, M. C. (1997). Strategies to minimize the development of antibiotic resistance. Journal of Chemotherapy 9, Suppl. 3, 29-37.
35. Baquero, F. (1996). Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative study. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 117-32.
36. Marchase, A., Mannelli, S., Tonoli, E. et al. (2001). Prevalence of antimicrobial resistance in Streptococcus pneumoniae circulating in Italy: results of the Italian Epidemiological Observatory Study (1997-1999). Microbial Drug Resistance 7, 277-87.
37. Baquero, F. (1999). Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolides? Journal of Chemotherapy 11, Suppl. A, 35-43.
38. Ball, P., Baquero, F., Cars, O. et al. (2002). Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimised resistance emergence. Journal of Antimicrobial Chemotherapy 49, 31-40.
39. Dagan, R., Klugman, K. P., Craig, W. A. et al. (2001). Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. Journal of Antimicrobial Chemotherapy 47, 129-40.
40. Garau, J. (2001). Clinical failures: the tip of the iceberg? Respiratory Medicine 95, Suppl. A, S5-11.
41. Moroney, J. F., Fiore, A. E., Harrison, L. H. et al. (2001). Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clinical Infectious Diseases 33, 797-805.
42. Kelley, M. A., Weber, D. J., Gilligan, P. et al. (2000). Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clinical Infectious Diseases 31, 1008-11.
43. Davidson, R., Cavalcanti, R., Brunton, J. L. et al. (2002). Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. New England Journal of Medicine 346, 747-50.
44. Jacobs, M. R. (2000). Increasing antibiotic resistance among otitis media pathogens and their susceptibility to oral agents based on pharmacodynamic parameters. Pediatric Infectious Diseases Journal 19, S47-56.